Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Non-Current Debt: 2019-2023

Historic Non-Current Debt for Seres Therapeutics (MCRB) over the last 5 years, with Dec 2023 value amounting to $101.5 million.

  • Seres Therapeutics' Non-Current Debt rose 1.74% to $102.5 million in Q2 2024 from the same period last year, while for Jun 2024 it was $102.5 million, marking a year-over-year increase of 1.74%. This contributed to the annual value of $101.5 million for FY2023, which is 100.72% up from last year.
  • Latest data reveals that Seres Therapeutics reported Non-Current Debt of $101.5 million as of FY2023, which was up 100.72% from $50.6 million recorded in FY2022.
  • In the past 5 years, Seres Therapeutics' Non-Current Debt registered a high of $101.5 million during FY2023, and its lowest value of $24.6 million during FY2020.
  • Its 3-year average for Non-Current Debt is $58.9 million, with a median of $50.6 million in 2022.
  • In the last 5 years, Seres Therapeutics' Non-Current Debt declined by 0.04% in 2020 and then surged by 105.30% in 2022.
  • Over the past 5 years, Seres Therapeutics' Non-Current Debt (Yearly) stood at $24.6 million in 2019, then declined by 0.04% to $24.6 million in 2020, then increased by 0.02% to $24.6 million in 2021, then soared by 105.30% to $50.6 million in 2022, then surged by 100.72% to $101.5 million in 2023.